Chambal Fert. Q1 FY27 Results (NSE: CHAMBLFERT)

· Analysis by Alpha Inflection

Signal: Revenue declined

The read

Q1FY27 saw a sharp revenue decline (-11.8% YoY) driven by Complex Fertilisers, but operating EBIT rose 7.6% YoY as Own Manufactured and Crop Protection held up, and costs were well controlled. The consolidated profit fell 4.6% YoY entirely due to the JV IMACID swinging to a loss and a surge in finance costs; standalone PAT grew 10.3% YoY, highlighting that the group's core fertiliser and crop protection operations are resilient. The margin arc shows a sixth consecutive quarter of EBITDA margin expansion (calc 17.1% vs 14.0% Q1FY26) driven by cost discipline and better product mix.

Chambal Fert. Q1 FY27 key financials
MetricValueYoYQoQ
Revenue₹5,027.02 Cr-11.8%+80.5%
EBIT₹771.82 Cr+7.6%
Net profit₹523.6 Cr-4.6%
EPS₹13.07-4.6%
EBIT margin15.5%

P&L walk

Revenue declined 11.8% YoY to ₹5,027 Cr, driven by a sharp fall in Complex Fertilisers segment revenue (₹1,736.66 Cr, -18.5% YoY) partially offset by sequential recovery from Q4’s ₹2,785 Cr. Operating EBIT (before finance cost, JV share) rose 7.6% YoY to ₹771.82 Cr, as Own Manufactured Fertilisers segment held steady (₹431.77 Cr, -6.4% YoY) and Crop Protection grew 12.7% YoY to ₹108.35 Cr. However, the JV IMACID swung from a profit of ₹36.12 Cr to a loss of ₹25.10 Cr, and unallocable other income net of expenditure dropped sharply (₹-9.71 Cr vs ₹-19.73 Cr YoY), while finance costs surged to ₹16.77 Cr (vs ₹2.43 Cr YoY) due to higher borrowings. Consequently, consolidated PAT fell 4.6% YoY to ₹523.60 Cr. Employee costs as a % of revenue rose 10bps YoY to 1.4%, but raw material costs as % of revenue improved 30bps YoY to 29.5%. Depreciation stayed flat YoY at ₹89.06 Cr.

Segments

Own Manufactured Fertilisers remained the anchor (segment profit ₹431.77 Cr, 55.5% of total segment profit), but Complex Fertilisers segment profit jumped from a loss of ₹11.51 Cr in Q4 to a profit of ₹238.71 Cr (up 67% YoY) due to seasonal rebound; Crop Protection segment profit grew 12.7% YoY to ₹108.35 Cr. The key drag was the joint venture IMACID (share of loss ₹25.10 Cr vs profit ₹36.12 Cr YoY), which reversed a multi-quarter profit stream.

Key positives

Key concerns

View original filing

Research and educational content only. Not investment advice.